ArticleFrontiers in immunology2026
Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Simultaneous Quantification of Multiple Immune Checkpoint Interactions in Melanoma.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CTLA-4/CD80 and PD-1/PD-L1 immune checkpoint pathways play critical roles in regulating T-cell activity within the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC). While immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have improved survival outcomes, response rates vary, and predictive biomarkers' alternative to PD-L1 expression are imperative. Our study aimed to identify PD-1/PD-L1 and CTLA-4/CD80 interaction states as enhanced predictive biomarkers for patient stratification to anti-PD-1/PD-L1 therapies in NSCLC. Methods: This study utilized the QF-Pro Results: Remarkably, we also identified high CTLA-4/CD80 interaction (FRET efficiency ≥6.41%) as correlating with improved OS and PFS in response to anti-PD-1/PD-L1 therapies. Patients with concurrently high PD-1/PD-L1 and CTLA-4/CD80 interactions exhibited the highest response rates, suggesting synergistic interplay between these checkpoints. In contrast, neither biomarker predicted response to chemotherapy in a separate cohort of 51 lung adenocarcinoma patients, confirming specificity for ICI therapy. Conclusions: These results highlight the potential of QF-Pro
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.